Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
Date:6/24/2011

PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ --


 

The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy.

Hemodiafiltration reduces mortality only if high substitution volumes are used

The prospective, randomised CONTRAST study (abstract no. 2507) aimed to evaluate whether treatment with HDF reduces overall mortality compared with low-flux HD. In the outcome there was no difference between the two groups regarding the incidence of overall mortality, but a subgroup analysis indicated that patients who had reached a substitution volume of over 20 litres/treatment had a significantly lower mortality risk than patients with lower substitution volumes (HR 0.66; p = 0.03).

The prospective, randomised, controlled TURKISH HDF study (abstract no. 2506) compared HDF with large pore hemodialysis (HD) in terms of morbidity and mortality. The difference in terms of mortality was not significant (p = 0.28), but a subgroup analysis showed that HDF patients with a high substitution volume of > 17.4 litres/treatment had a significantly better cardiovascular and overall survival rate.

Bardoxolone improves renal function in type II diabetics with nephropathy

A double-blind, placebo-controlled multi-centre phase II study (abstract no. 2501) randomized 227 type II diabetics with moderate to severe CKD (eGFR 20-45 ml/min/1.73m?) in four different groups.

Significant improvements in GFR were reported in all the bardoxolone groups compared to the placebo group (p<0.001). Other renal function parameters (creatinine and urea) were also better in the Bardoxolone group.

For further information, please see:

http://www.eraedta2011.org/press.html

Bettina Albers

3643776423

albers@albersconcept.de



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
2. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
3. ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics
6. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
7. Former U.S. Congressman Curt Weldon to Represent Regenicin at 2011 Future of Financial Markets Conference in Mumbai
8. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
9. Brazilian Sugarcane Industry Association Says Lame-Duck Congress Goes from Bad to Worse on Ethanol Policy
10. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
11. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
Breaking Biology News(10 mins):